Objectives-To analyse the immunological interactions between the gut lymphoid tissue, synovium, and peripheral blood compartnents in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Methods-Patients with RA and AS and healthy controls were oraliy or parenterally immunised with an influenza virus vaccine. Antigen-specific antibody responses were measured at the single cell level by ELISPOT assay using lymphocytes isolated from peripheral blood and from enzymatically dispersed synovial tissues.
Results-Both oral and parenteral immunisations induced antigen-specific antibody-secreting cells in the synovial tissue of patients with RA. Parenterally immunised patients with RA showed significantly decreased antigen-specific antibody responses in peripheral blood compared with patients with AS and with healthy controls. In contrast, oral vaccination evoked comparable peripheral blood antibody responses in all three study groups.
Conclusions-Despite a decreased immune responsiveness in the systemic compartment, the functional status of the gut-associated lymphoid tissue in patients with RA is intact. In addition, there is evidence that the lymphocytes in the inflamed joints are accessible for signals both from the systemic and mucosal compartments. The findings of immunological 'cross-talk' are relevant to future vaccination and tolerisation procedures in patients with RA.
(Ann Rheum Dis 1994; 53: 377-382) At present there is scant information on the immunological status of the gastrointestinal tract in patients with rheumatic diseases.' 2 The uptake of molecules from the gut is regulated by mechanical, physical and immunological mechanisms.3 Disturbances of the mucosal barrier are observed in many intestinal diseases such as Whipple's disease and ulcerative colitis, where arthritis may occasionally occur.4 Also, studies of the gut in patients with primarily non-intestinal diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) indicate that aberrancies in the gastrointestinal tract may occur. 6 7 Changes of gastrointestinal permeability,8 9 altered pattern of bacterial colonisation'0 " as well as beneficial effects of fasting have been reported in patients with RA. 12 Furthermore, fasting has been shown to ameliorate the disease activity and simultaneously decrease the bowel permeability in patients with RA.3 Direct evidence for the role of the gastrointestinal tract in the immunoregulation of experimental arthritis has been demonstrated by the tolerogenic effects of an oral administration of type II collagen in an experimental rat model with RA. '4 Despite the evidence that the immune system of the gastrointestinal tract may modulate experimental arthritis, the gutassociated lymphoid system has not been carefully studied in rheumatic patients. We therefore set up a model system for evaluation of the gut-associated lymphoid system as an inductive site for an antigen-specific immune response. This is performed by oral immunisation with killed influenza virus vaccine and subsequent assessment of peripheral blood B-lymphocyte responses at the single cell level. In addition, synovial tissue lymphocytes obtained from patients with RA, were analysed regarding antigen-specific antibody production in response to the mucosal influenza vaccine challenge.
There are conflicting data concerning the systemic B-cell responsiveness in patients with RA, both at the cellular and humoral level. Hypo-and hyperreactivity as well as intact immune responses have been reported. '5-18 To analyse the systemic B-cell responsiveness at the single cell level rheumatic patients were immunised perenterally with influenza vaccine.
Methods

SUBJECTS AND VACCINE
The table provides a summary of experimental procedures and clinical features of patients included in this study. We believe that all participants in this study have been previously naturally exposed to the influenza virus. Thus we consider that all the B-cell responses to influenza vaccine seen are of secondary nature. In the first set of experiments 25 patients with RA, 9 (10) 36 (8) 58 (15) 53 (17) 42 ( 11) 40 (12) 61 (13) 20 (12) The ELISPOT assay was used to determine the numbers of immunoglobulin secreting cells of a given isotype and of antigen-specific antibody secreting cells. The principle of this assay has been described elsewhere." Briefly, a single cell suspension of lymphocytes is incubated on a solid phase coated with a relevant antigen, followed by an immunoenzymatic procedure which will allow the visualisation of antigen-specific B-cells as singular dark spots. Wells in the lids of 24 
Results
To assess the functional properties of the gutassociated lymphoid tissue, patients with RA, AS and healthy controls were orally immunised with an influenza virus vaccine and the subsequent immune response was recorded in the blood at the single cell level. No side effects of the oral immunisation were observed in any subject. To exclude variations in the kinetic pattern of the immune responsiveness to the antigen between patients with RA, AS and controls, PBMC from one subject in each group were analysed at days 0, 4, 7 and 10. The kinetics of the antigen specific antibody production was very similar for these three subjects: no influenza-specific SFCs at day 0, a few at day 4, a peak response at day 7, and a decreasing number of SFCs at day 10 ( fig 1) . In the second set of experiments the impact of a parenteral vaccination with influenza vaccine on the frequency of antigen-specific SFC was analysed in peripheral blood. Before the immunisation antigen specific SFCs were not detected. Seven days later antigen specific SFCs were found in all but one (a patient with RA) subjects. This antigen-specific B-cell response to the influenza vaccine was 10-50 fold higher than that recorded in orally immunised subjects ( fig 2B) . The number of influenza-specific SFCs of IgG-class after parenteral immunisation was significantly lower in patients with RA compared with controls (p < 001) and patients with AS (p < 0 05). A similar, although not statistically significant trend was seen for IgA-specific B-cell responses. In contrast, the antigenspecific IgM responses were similar in all groups. There was no significant difference for the magnitude of the antigen-specific B-cell response in patients with RA treated with cytotoxic drugs compared with other forms of pharmacotherapy. (fig 3) . This response was significantly higher compared with patients with RA who had not been immunised (fig 3) . The frequency of responders in each group was 6/10 for the orally immunised and 7/9 for the parenterally immunised. In contrast, only in two of the 12 non-immunised patients could a few antigen-specific antibody producing cells be detected (fig 3) . The magnitude of the B-cell response was on average four fold higher in parenterally immunised subjects compared with that seen in orally immunised subjects. Notably, in one orally immunised patient we found antigen-specific SFC in the synovium but not in the peripheral blood. To analyse the propensity of influenza antigen committed antigen-specific B-cells triggered by oral exposure display a strong propensity to home to synovium compared with circulating B-cells triggered by parenteral immunisation. Thirdly, the oral immunisation might have activated antigen-specific mucosal T-cells. After migration and homing to the synovial tissue these T-cells could interact with antigencommitted B-cells to induce an antibody production. Our preliminary data indicate that the cell-surface marker HML1, restricted to intra-epithelial T-lymphocytes in the gut,34 is also found on some synovial lymphocytes. A site-directed traffic of lymphocytes from the gut to the articular compartment would raise the possibility of oral vaccination against, for example, septic arthritis, and of oral tolerance induction to collagen type II or proteoglycans.
We have recently shown that human synovial tissue exerts strong antigen presenting properties.2' Our present results, together with our previous report favour bilateral communication between articular and systemic lymphoid compartments. These findings are important since an intact function of the gutassociated lymphoid tissue and an immunological connection between extra-articular and synovial compartments are prerequisites for future vaccination and toleration studies in RA. Recent results35 36 suggest that oral toleration may be a valuable treatment of certain autoimmune diseases. 
